There is currently a pandemic of respiratory disease caused by a novel coronavirus (SARS-CoV-2) named “Coronavirus Disease 2019” (COVID-19). SARS-CoV-2 has demonstrated the capability to spread rapidly, leading to significant impacts on healthcare systems and causing societal disruption. The potential public health threat posed by COVID-19 is high, both to the United States and globally. To effectively respond to the COVID-19 outbreak, rapid detection of cases, appropriate clinical management, infection control, and implementation of community mitigation efforts are all critical.
Under the FDA’s Emergency Use Authorization (EUA) for diagnostic testing, GeneIQ is committed to providing access to COVID-19 testing solutions with high-quality, high-throughput RT-PCR based assays.